An Integrated Approach to Breast Cancer Control A flexible approach that can be adapted to national or local circumstances.

Slides:



Advertisements
Similar presentations
Implementing NICE guidance
Advertisements

Every Womans Life PROGRAM MANUAL UPDATE
Planning M&E to Tell Our ACSM Story. Objectives Discuss how ACSM activities can address barriers to help reach national TB control targets. Describe how.
Donald T. Simeon Caribbean Health Research Council
†Source: U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2011 Incidence and Mortality Web-based Report. Atlanta (GA): Department.
Prostate Cancer Support Federation Charity Nº: We have no national screening programme for the most common cancer in men and the only test we.
Somaiya Medical College and Maina Foundation Five Year Project for Raising breast Cancer Awareness in Pratikshanagar - Mumbai.
Linking Multilevel Analysis to Health Policy Interventions Richard B. Warnecke, Sarah Gehlert, Carol Ferrans, Richard Barrett, Julie Darnell, Young Cho,
Purposes and uses of cancer registration E.E.U. Akang Department of Pathology University College Hospital Ibadan, Nigeria.
Use Case 7 IHE Profiles & Actors Care Theme: Leveraging Healthcare Registries in Care Delivery Use Case: Optimizing Cancer Care Coordination Leveraging.
How are cancer statistics kept up to date?.  Example:  Dx stage II colon cancer  Cancer has metastasized to the liver – 2009  How does the.
Early Detection of breast cancer Anthony B. Miller, MD, FRCP Associate Director, Research, Dalla Lana School of Public Health, University of Toronto, Canada.
THE GUYANA CANCER REGISTRY PRESENTED BY: Penelope Layne: RN,RM,Dp.OSH, BSC Nursing Mangement REGISTRAR GUYANA CANCER REGISTRY July 2013 PRESENTED BY: Penelope.
BREAST AND CERVICAL CANCER CONTROL PROGRAM Emily Vance Nursing 250.
Quality Cancer Data The Vital Role of Cancer Registrars in the Fight against Cancer Saves Lives.
CERVICAL CANCER: EARLY DETECTION, DIAGNOSIS & TREATMENT in LRS By Dr D. A. Kombe, MD, Mmed (Rad/onc) 2 nd East Africa WE CAN Breast & Cacx Advocacy, Education.
Surveillance to measure impact of ART Theresa Diaz, MD MPH CDC Global AIDS Program.
Racial/Ethnic Disparities in Cancer Incidence, Survival and Treatment Linda C. Harlan, PhD, MPH National Cancer Institute Division of Cancer Control and.
Mammography Screening Information for Providers Indian Health Service National GPRA Team.
Jo Anne Zujewski, MD Cancer Therapy Evaluation Program Division of Cancer Diagnosis and Treatment National Cancer Institute January
Kenya Field Epidemiology and Laboratory Training Program (KFELTP)
Unit 1: Overview of HIV/AIDS Case Reporting #6-0-1.
Session Fertility and Pregnancy FL-BBM Specific questions Risk of premature ovarian failure Ability to become pregnant Safety of pregnancy.
ADAPT serving geriatric populations in rural communities. Project ADAPT Assessing Depression and Proactive Treatment The Minnesota Area Geriatric Education.
Implementing universal Lynch Syndrome screening in a large healthcare system.
Components of HIV/AIDS Case Surveillance: Case Report Forms and Sources.
“The African American Prostate Cancer Crisis in Numbers”
Bias Defined as any systematic error in a study that results in an incorrect estimate of association between exposure and risk of disease. To err is human.
Unit 3: Universal Case Reporting and Sentinel Surveillance for STIs
California Stroke Registry Right Care Initiative Meeting August 13, 2012.
SEER Provided Data Mohammad Afnan Baqai 12/3/2009.
CHP400: Community Health Program-lI Mohamed M. B. Alnoor Muna M H Diab SCREENING.
Data Sources-Cancer Betsy A. Kohler, MPH, CTR Director, Cancer Epidemiology Services New Jersey Department of Health and Senior Services.
Module 3. Session Clinical Audit Prepared by J Moorman.
 Volunteer bias  Lead time bias  Length bias  Stage migration bias  Pseudodisease.
Linda Devereux Associate Director Merseyside and Cheshire Cancer Network - why we are here and what’s next!
Cancer Mortality Target Measuring and Monitoring at a National Level Jennifer Benjamin, Department of Health Kathy Elliott, National Cancer Action Team.
Joni Reynolds, RN-CNS, MSN Director of Public Health Programs Winnable Battles: Cancer in Colorado.
Incorporating Multiple Evidence Sources for the Assessment of Breast Cancer Policies and Practices J. Jackson-Thompson, Gentry White, Missouri Cancer Registry,
Screening of diseases Dr Zhian S Ramzi Screening 1 Dr. Zhian S Ramzi.
Screening and its Useful Tools Thomas Songer, PhD Basic Epidemiology South Asian Cardiovascular Research Methodology Workshop.
Indicators in Malaria Program Phases By Bayo S Fatunmbi [Technical Officer, Monitoring & Evaluation] ERAR-GMS, WHO Cambodia & Dr. Michael Lynch Epidemiologist.
Indicators in Malaria Program Phases By Bayo S Fatunmbi [Technical Officer, Monitoring & Evaluation] ERAR-GMS, WHO Cambodia.
Older People’s Services The Single Assessment Process.
Unit 15: Screening. Unit 15 Learning Objectives: 1.Understand the role of screening in the secondary prevention of disease. 2.Recognize the characteristics.
Digital Imaging in Education and Distributed Pathology Practice
The Inflammatory Breast Cancer Cancer Registry Paul H. Levine, M.D. Paul H. Levine, M.D. The George Washington University School of Public Health and Health.
StagesOf Assessment Stages Of Assessment. The Stages of Assessment for the Single Assessment Process §Publishing information about services. §Completing.
2015 Cancer Program Performance Outcomes. Introduction Saint Agnes Medical Center has proudly maintained a American College of Surgeons’ Commission on.
Health Care Delivery System.  About 75 percent of the total population of the barangay are being served, Because some of the people of the Barangay goes.
1 April 2010 Jhpiego/Baltimore Veronica Reis, MD, MPH MCHIP Technical Director MAPUTO, MOZAMBIQUE BREAST AND CERVICAL CANCER PREVENTION ACTIVITIES INTEGRATED.
Analytical Studies Case – Control Studies By Dr. Sameh Zaytoun (MBBch, DPH, DM, FRCP(Manch), DTM&H(UK),Dr.PH) University of Alexandria - Egypt Consultant.
GEOGRAPHIC DISTRIBUTION OF BREAST CANCER IN MISSOURI, Faustine Williams, MS., MPH, Stephen Jeanetta, Ph.D. Department of Rural Sociology, Division.
Session 6: Data Flow, Data Management, and Data Quality.
The Cancer Registry of Norway Jan F Nygård Head of the IT-department.
Quality & Sustainability in Cancer Control: A System Performance Spotlight Report To use a hyperlink, right click on it and select ‘Open Hyperlink’, or.
Date of download: 5/31/2016 From: Tipping the Balance of Benefits and Harms to Favor Screening Mammography Starting at Age 40 Years: A Comparative Modeling.
© 2010 Jones and Bartlett Publishers, LLC. Chapter 12 Clinical Epidemiology.
Provider Initiated HIV Counseling and Testing Unit 2: Introduction and Rational for PIHCT.
Evaluation of the Community Patient Navigation Program within the Community Education and Outreach Initiative (CEOI) Patient Navigation is one strategy.
1 Module 2: HIV Counseling and Testing for PMTCT Ministry of Health/HAPCO, Ethiopia.
Screening Tests: A Review. Learning Objectives: 1.Understand the role of screening in the secondary prevention of disease. 2.Recognize the characteristics.
Dr. Kęstutis Adamonis, Dr. Romanas Zykus,
TMIST A Breast Cancer Screening Trial
Quality issues in monitoring diagnostic and treatment performance Dr
Definition of Cancer Screening
From: Tipping the Balance of Benefits and Harms to Favor Screening Mammography Starting at Age 40 YearsA Comparative Modeling Study of Risk Ann Intern.
Megan Eguchi, MPh Sana karam, md, phd
STEPS Site Report.
Presentation transcript:

An Integrated Approach to Breast Cancer Control A flexible approach that can be adapted to national or local circumstances

Incidence and Mortality

Age-Specific Incidence

Age-Specific Mortality

Linking Early Detection with Treatment Screen Positive Mortality data (Screened or study patients or population) Screened Diagnosis made/not Staged or not Refuse therapy Receive therapy after delay (good/bad) Receive prompt therapy (good/bad) Survival for x years

Outline of an Approach  Education/recruitment and screening are undertaken at multiple peripheral sites – community health centers – or a mobile site  Peripheral sites screen either by CBE or mammography, complete relevant data modules and send to the data center, or enter data via an internet site.  Mammograms, if done could be read immediately, at intervals of a few days, or digital transmission could be used  Second reading of mammogram may be performed at a referral center, either national site or international by film or digital transmission –Improves quality –A valuable training opportunity  Screen positive persons are referred to a regional hospital or the cancer center for diagnosis, and treatment and completion of additional data modules  All treatment decisions are taken by a combined team of surgeon, radiation and medical oncologists. Ideally, the treatment approach should be defined and identical for screened and unscreened patients.  Treatment progress and outcome is recorded on data forms

Mammography versus CBE  In most low and middle income countries, it will not be possible to undertake large screening mammography programs because of limited availability of equipment, technical and professional expertise, and the potential impact on other health programs  Clinical breast examination may be performed instead. This requires less equipment, but well trained personnel to do the examination – in some countries, only doctors are allowed to  Some screening centers may use one method and some another –Ultrasound may also be considered, although this also requires equipment (more readily available) and skilled professionals –If enough women are screened, the pros and cons of each approach can be examined –Over time, more women may undergo mammography as additional machines are acquired and expertise developed  Whatever methods are adopted, quality assurance is required

Comparison with Unscreened Patients  At all hospital sites, until total screening coverage is obtained unscreened patients will continue to present.  Such patients can be compared to screened patients (if required, separately for CBE and mammography) with respect to stage of disease, treatment administered and treatment outcome, (if followed up).  A third group of patients that may need separate analysis are screen negative patients presenting some time after screening

Mammography Site Hospital/ Cancer Center Registry/ Data Center Community Health Center/Clinic

Logigram Central Diagnostic And Treatment Facility Data Center District or Gynae Hospital; Biopsy, Screening Mammography? Educational Recruitment and Screening Facilities; Screen Positive Persons Referred for Diagnosis and Treatment Standard (Unscreened) Referrals From Primary Care Physicians or Other Sources Some Interval Occurrences in Previously screen Negative Persons Records of all patients screened and all diagnoses made are kept at each institution/clinic and provided to the Data Center

Data Collection  It is imperative to collect data at all steps in the process  Each participating clinic/hospital/center should be assigned a number  Each person screened or presenting with possible breast cancer should be assigned a number  Personal identifiers may include name and address for purposes of contacting the person, but data can be readily anonymized for purposes of analysis or submission to the data center if required  Project coordination can be from within the country or outside the country (e.g., via data transmissions by e- mail or direct data entry into a web site.

Data Collection Templates Module 1: Identifiers and Demographics Module 2: Education Module 3: Recruitment Module 4: Clinical Breast Examination Module 5: Mammography Module 6: Diagnostic Work-up Screen Positive Module 7: Referral - no screening Module 8: Consultation; not screened Module 9: Pathology Module 10: Epidemiology Module 11: Family History; females Module 12: Family History; males Module 13: Past History Module 14: Disease Sites Module 15: Stage Module 16: Receptor Status Module 17: Treatment Module 18: Treatment Response Use of Modules Detection center: or 5 Diagnostic center: Treatment center: 13 – 18 Optional: 10 – 12 Summary Modules Module 19: Summary - Overview Module 20: Summary - Screening Center Module 21: Summary - Diagnostic Center Module 22: Summary - Treatment Center

Implementation  Implementation of an integrated program for breast cancer control will require a number of steps to be taken, including: –Identification of all key figures and involvement in decisions about the program –Identify screening sites, diagnostic sites and treatment sites and develop uniform approaches to each element, including data collection –Identify training needs, additional staff and trainers, and develop appropriate curricula

Outcome Measures  Extent of disease and survival in screened and unscreened patients –stage distribution –overall survival and survival by stage  Delay in diagnosis and in initiating treatment: –Time from first symptom to the start of treatment in screened and unscreened patients –Time from screening to the start of treatment in screen positive patients –Time to diagnosis and time from diagnosis to definitive treatment in screen positive patients

Potential Weaknesses  The study is not randomized, such that if differences between screened and unscreened patients are found, these could be, in part, due to biases: –Patients with slowly growing disease may account for a higher fraction of cases in the screened group –Patients may appear to survive longer if detected earlier (by screening).  In patients screened for the first time, these biases may be overwhelmed by the detection of patients with relatively advanced cancer who have not sought medical advice and have a poor treatment outcome  Unless treatment is identical for all patients, differences in survival may arise from differences in treatment  If a high fraction of patients refuse therapy, survival (or mortality) comparisons will be difficult or impossible to interpret

Strengths  Although the study design has weaknesses, it will lead to more uniform and disciplined treatment of women with breast cancer  Since all women will be followed up, better information on response to therapy and survival, regardless of how the cancer is detected, should be obtained  This approach should provide an indication of the benefits (or lack of benefits) of screening, although such benefits may change over time due to: –Increased awareness of breast cancer (whether from directed programs or not), may result in overall earlier stage and an improved treatment outcome even in unscreened women. –If screening is performed at 2-5 year intervals, the first screening round is likely to include more patients with advanced cancer who have previously failed to take medical advice.  If data is collected, the effect on outcome of various subgroups within the populations can be examined and biases quantified

Medline Bibliography Breast cancer control in developing countries